Drugs / CAMIBIRSTAT
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07283094 | Feb 2026 → May 2028 expected | acute myeloid leukemia, myelodysplastic syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04891757 | Jun 2021 → Sep 2025 overdue | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Foghorn Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04879017 | May 2021 → Nov 2023 | uveal melanoma | Foghorn Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07551635 | Sep 2026 → Jan 2028 expected | small cell lung carcinoma | Dana-Farber Cancer Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAMIBIRSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095181 ↗ |
| Known as | FHD-286 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04891757 ↗ |
| Action | Inhibit | “FHD-286, a dual BRG1/BRM (Brahma related gene 1/Brahma homolog) inhibitor” PMID 40238563 ↗ Jun 2025 |
| Modality | Small molecule | “a small-molecule SMARCA4/2 ATPase (BRG1 and BRM) inhibitor” NCT07551635 ↗ |
| Route | Oral | “when administered orally to subjects” NCT04879017 ↗ |
| Target | SMARCA2 | “FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor” PMID 40238563 ↗ Jun 2025 |